Spotlight on landmark oncology trials: the latest evidence and novel trial designs.

about

Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian Cancer.

P2860

Q54993659-5353F729-748C-4157-8CED-30E31F601C1F

P2860

Spotlight on landmark oncology trials: the latest evidence and novel trial designs.

Item

http://www.wikidata.org/entity/Q42343618

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Spotlight on landmark oncology trials: the latest evidence and novel trial designs.

@en

Spotlight on landmark oncology trials: the latest evidence and novel trial designs.

@nl

type

Item

label

Spotlight on landmark oncology trials: the latest evidence and novel trial designs.

@en

Spotlight on landmark oncology trials: the latest evidence and novel trial designs.

@nl

prefLabel

Spotlight on landmark oncology trials: the latest evidence and novel trial designs.

@en

Spotlight on landmark oncology trials: the latest evidence and novel trial designs.

@nl

P1476

Spotlight on landmark oncology trials: the latest evidence and novel trial designs

@en

P2093

Stefano Molica

http://www.w3.org/2001/XMLSchema#string

P2860

Advances in immunotherapy for melanoma

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Nivolumab in previously untreated melanoma without BRAF mutation

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

P2888

s12916-017-0884-7

P304

111

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1186/S12916-017-0884-7

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Helena Earl

Piotr Rutkowski

P577

2017-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085742240

http://www.w3.org/2001/XMLSchema#string

P698

28571584

http://www.w3.org/2001/XMLSchema#string

P932

5454584

http://www.w3.org/2001/XMLSchema#string

Spotlight on landmark oncology trials: the latest evidence and novel trial designs.

about

P2860

P2860

Spotlight on landmark oncology trials: the latest evidence and novel trial designs.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P932